EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hypertensive toxicity of thyrosine kinase inhibitors; Friend or Foe?

Ergün Barış Kaya, Yusuf Ziya Şener

Annals of Clinical Hypertension · 2021

DOI: 10.29328/journal.ach.1001025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical Hypertension, 2021. Verfasst von Ergün Barış Kaya und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tyrosine kinase inhibitors (TKIs) are widely used in Oncology practice. Hypertension may develop during cancer treatment and TKIs are well known drugs that are associated with drug related hypertensive toxicity. TKI related hypertensive toxicity is not always the indicator of worse clinical outcomes and it may be the sign of treatment efficacy.

Zitieren

APA

Kaya, E. B., & Şener, Y. Z. (2021). Hypertensive toxicity of thyrosine kinase inhibitors; Friend or Foe?. Annals of Clinical Hypertension. https://doi.org/10.29328/journal.ach.1001025

Vancouver

Kaya EB, Şener YZ. Hypertensive toxicity of thyrosine kinase inhibitors; Friend or Foe?. Annals of Clinical Hypertension. 2021. doi:10.29328/journal.ach.1001025

BibTeX
@article{Kaya2021,
  author = {Kaya, Ergün Barış and Şener, Yusuf Ziya},
  title = {Hypertensive toxicity of thyrosine kinase inhibitors; Friend or Foe?},
  journal = {Annals of Clinical Hypertension},
  year = {2021},
  doi = {10.29328/journal.ach.1001025}
}
Kostenlos starten →